Clinical Trials Logo

Varicella Zoster clinical trials

View clinical trials related to Varicella Zoster.

Filter by:
  • None
  • Page 1

NCT ID: NCT06162494 Not yet recruiting - Varicella Zoster Clinical Trials

Recombinant Zoster Vaccine in Young Adult Solid Organ Transplant Recipients

Start date: December 5, 2023
Phase: Phase 4
Study type: Interventional

This goal of this study is to assess the safety and immunogenicity of recombinant zoster virus in young adult solid organ transplant recipients. In this study, participants will receive the recombinant zoster vaccine. They will be monitored for adverse events and tested for antibody and cellular immunity.

NCT ID: NCT06075732 Not yet recruiting - COVID-19 Clinical Trials

ACTIVATE in Public Housing

Start date: July 1, 2024
Phase: N/A
Study type: Interventional

This multilevel, multidisciplinary, theoretically based, culturally sensitive, community-engaged intervention sets out to mitigate uptake barriers and non-adherence to vaccination schedules as recommended by the CDC and increase influenza, meningitis, pneumonia, VZV, and COVID-19 vaccine rates among under-resourced African American and Latino public housing residents in South Los Angeles.

NCT ID: NCT04099706 Completed - Chronic Pain Clinical Trials

Treatment of Chronic Postherpetic Pain With Autologous Fat Grafting - A RCT

Start date: September 19, 2019
Phase: N/A
Study type: Interventional

This randomized clinical trial investigates the possible beneficial effect of autologous fat grafting on postherpetic neuralgia.

NCT ID: NCT03820414 Completed - Herpes Zoster Clinical Trials

Safety, Tolerability, and Immunogenicity of CRV-101 in Healthy Adult Subjects

Start date: January 3, 2019
Phase: Phase 1
Study type: Interventional

The purpose of this clinical trial is to evaluate the safety, tolerability, and immunogenicity of vaccine candidate CRV-101, investigational vaccine in healthy adult subjects in the United States.

NCT ID: NCT03178747 Recruiting - Herpes Zoster Clinical Trials

Tzanck Smear With Methylene Blue Stain for Herpes

Start date: March 7, 2017
Phase: Phase 3
Study type: Interventional

To compare the sensitivity of Tzanck smear with methylene blue stain versus traditional Giemsa stain in patients with herpes infection.

NCT ID: NCT03121638 Completed - Clinical trials for Immunization; Infection

Safety Study of NBP608 in Healthy Adult Volunteers

Start date: November 2012
Phase: Phase 1
Study type: Interventional

- Indication: Protection against varicella and herpes zoster - Study Objectives - Primary: Safety and tolerability assessment after single dose administration of NBP608 - Secondary: immunogenicity assessment after single dose administration of NBP608

NCT ID: NCT02559596 Withdrawn - Stroke Clinical Trials

Reactivation of Varicella Zoster Virus and Risk of Vascular Disease

Start date: June 2015
Phase:
Study type: Observational

The purpose of this study is to investigate whether there is an association between stroke or heart attack and reactivation of varicella zoster virus, measured by antibody levels, using linked data from the Health Survey for England and secondary care.

NCT ID: NCT01506661 Completed - Clinical trials for Rheumatoid Arthritis

Safety of Zostavax Vaccination in Rheumatoid Arthritis

Start date: January 2012
Phase: Phase 1
Study type: Interventional

Herpes Zoster (shingles) is caused by reactivation of latent varicella zoster virus (VZV) that usually occurs decades following initial exposure. The risk of developing shingles increases with age. Shingles presents as a painful, itchy blistering rash that usually involves a single portion of the skin and lasts about 7-10 days. The risk of developing shingles increases with age in healthy people, and has been shown in some studies to be increased in people with rheumatoid arthritis and other autoimmune diseases. Zostavax, a live-attenuated vaccine against the varicella zoster virus, was first approved by the FDA for the prevention of Shingles among people 60 years and older, and is now approved for use in people aged 50 years and older. Because rheumatoid arthritis and some of the medications used to treat rheumatoid arthritis can impair the body's immune system, it is not known how much of an immune response can be generated in people with rheumatoid arthritis. The goals of this study are to measure the immune response after standard vaccination with Zostavax in people with rheumatoid arthritis in comparison to people with healthy immune systems. All participants will be 50 years old or older, and subjects with rheumatoid arthritis will not be eligible if they are taking certain biologic medications, including TNF inhibitors (Etanercept or Adalimumab). Ten healthy subjects and 10 subjects with rheumatoid arthritis will all receive a single vaccination with Zostavax, then will be followed for 12 weeks to assess the immune response and for the development of local rash or other potential side effects.